Advancing Drug Resistance Detection: Comparative Analysis Using Short-Read and Long-Read Next-Generation Sequencing Technologies
Authors:
- Julie MartinezJMJulie Martinez
- Rezak DraliRDRezak Drali
- Amira DoudouADAmira Doudou
- Chalom SayadaCSChalom Sayada
- Ronan BoulméRBRonan Boulmé
- Dimitri GonzalezDGDimitri Gonzalez
- Laurent DeblirLDLaurent Deblir
- Matthieu BarralonMBMatthieu Barralon
- Jérome WautrinJWJérome Wautrin
- Jonathan PorzioJPJonathan Porzio
- Arnaud ReffayARArnaud Reffay
- Mohamed ErrafyqyMEMohamed Errafyqy
Open Access
Abstract
In recent years, antiviral therapy has proved crucial in the treatment of infectious diseases, particularly infections by highly variable viruses such as human immunodeficiency virus, hepatitis B, hepatitis C, SARS-CoV-2 or bacteria such as Mycobacterium tuberculosis. Under the effect of selection pressure, this variability induces mutations that lead to resistance to antiviral and antibacterial drugs, and thus to escape from treatment. The use of Advanced Biological Laboratories (ABL) assays technology combined with next-generation sequencing (NGS) and automatized software to detect majority and minority variants involved in treatment resistance has become a mainstay for establishing therapeutic strategies. The present study demonstrated high concordance between majority and minority subtypes and mutations identified in 15 samples across four NGS platforms: ISeq100 (Illumina (San Diego, CA, USA)), MiSeq (Illumina), DNBSEQ-G400 (MGI (Santa Clara, CA, USA)) and Mk1C MinION (Oxford Nanopore (Oxford Science Park, UK)). However, nanopore technology showed a higher number of minority mutations (® bioinformatics software, compatible with all four sequencing platforms. This study underlines the constant evolution of microbiological diagnostic research and the need to adapt rapidly to improve patient care.Keywords
This publication has 13 references indexed in Scilit:
- Comparison of iSeq and MiSeq as the two platforms for 16S rRNA sequencing in the study of the gut of rat microbiomeApplied Microbiology and Biotechnology, 2022
- Reducing costs for DNA and RNA sequencing by sample pooling using a metagenomic approachBMC Genomics, 2022
- Perspectives d’élimination de la tuberculose : la stratégie OMS à l’épreuve de la pandémie de COVID-19Médecine et Maladies Infectieuses Formation, 2022
- Nanopore sequencing technology, bioinformatics and applicationsNature Biotechnology, 2021
- Comparative analysis of 7 short-read sequencing platforms using the Korean Reference Genome: MGI and Illumina sequencing benchmark for whole-genome sequencingGigaScience, 2021
- On the utility of RNA sample pooling to optimize cost and statistical power in RNA sequencing experimentsBMC Genomics, 2020
- Nanopore sequencing: Review of potential applications in functional genomicsDevelopment, Growth & Differentiation, 2019
- Assessing the performance of the Oxford Nanopore Technologies MinIONBiomolecular Detection and Quantification, 2015
- Comparison of ultra-deep versus Sanger sequencing detection of minority mutations on the HIV-1 drug resistance interpretations after virological failureAIDS, 2014
- Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitorsAntiviral Therapy, 2009